Gle1 and IP~6~ robustly activate the ATPase activity of Dbp5[@R10], [@R11], but interactions between Dbp5 and Gle1~IP6~ are weak and transient *in vitro*[@R10], [@R12]. However, gain-of-function mutations in Dbp5 and Gle1 (Dbp5^L327V^ and Gle1^H337R^)[@R10] allowed for the purification of a stable Dbp5-Gle1~IP6~ complex for protein crystallography (data not shown). Multiwavelength anomalous dispersion (MAD) phased protein crystal structures were initially obtained for Gle1~IP6~ and the C-terminal RecA-like domain (CTD) of Dbp5^L327V^, both in the presence and absence of the Gle1 H337R mutation at a resolution of 2.6 Å (R~work~/R~free~ of 18.7%/21.3%) and 2.5 Å (R~work~/R~free~ of 20.2%/23.8%), respectively ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). This model allowed us to solve the crystal structure of an N-terminally truncated Δ90Dbp5^L327V^ construct containing both RecA-like domains of Dbp5 (residues 91--482) bound to ADP and Gle1^H337R^~IP6~ (residues 244--538) by molecular replacement at a resolution of 4.0 Å (R~work~/R~free~ of 21.4%/23.9%) ([Fig. 1](#F1){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Structures were also obtained for Δ90Dbp5^L327^ or Δ90Dbp5^WT^ in complex with RNA and ADP BeF~3~ at a resolution of 1.5 Å (R~work~/R~free~ of 16.5%/18.9%) and 1.4 Å (R~work~/R~free~ of 16.0%/18.0%), respectively ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

The structures reveal that Gle1 comprises an all α-helical HEAT repeat protein that makes contact with both RecA-like domains of Dbp5 ([Fig. 1a--b](#F1){ref-type="fig"}). The CTD interface buries 2230 Å^2^ of surface area, and contains a number of residues previously shown to be important for Gle1-mediated activation of Dbp5[@R12]. The second interaction surface uses the N-terminal RecA-like domain (NTD) of Dbp5 and an exposed hydrophobic α-helix of Gle1, which buries an additional 930 Å^2^ of surface area ([Fig. 1a](#F1){ref-type="fig"}). Interestingly, and despite the lack of obvious homology in sequence alignments, a search of the structural database using the DALI server[@R13] showed that the Gle1-fold is similar to that of eIF4G (14% identity, 4.1Å root mean squared deviation), a cofactor for the SF2 DEAD-box ATPase eIF4A[@R14]--[@R16], and to that of Upf2 (8% identity, 3.0 Å root mean squared deviation), which stimulates the SF1 protein Upf1[@R17]--[@R19].

A unique feature of the Gle1~IP6~-Dbp5 structures is the presence of IP~6~, which bridges the protein- protein interaction by binding in a positively charged pocket at the interface between Gle1 and the CTD of Dbp5 ([Fig. 1b--c](#F1){ref-type="fig"}). Residues K264/K333/H337/R374/K377/K378 in Gle1 and K477/K481 in Dbp5 interact with phosphate groups in IP~6~ ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Fig. 1a-- b](#SD1){ref-type="supplementary-material"}). Two of these residues in Gle1 (K377 and K378) were recently identified as being involved in IP~6~ binding[@R20]. Gle1 residues (H337/R374/K377/K378) show charge conservation, and Dbp5 residue K477 is conserved as a hydrogen bond donor in most metazoans, suggesting an evolutionary pressure to maintain a polar residue that can interact with IP~6~ at these positions. ([Supplementary Fig. 1c--d](#SD1){ref-type="supplementary-material"}). To our knowledge, this represents the first structural characterization of an endogenous small molecule that localizes at the interface of two heterologous proteins to mediate a protein-protein binding interaction.

To assess the importance of IP~6~ binding by Dbp5, we mutated the Dbp5-IP~6~ contacts K477 and K481 to Ala (Dbp5^KK→AA^). Dbp5^KK→AA^ exhibited no synergistic ATPase activation in the presence of IP~6~, RNA, and sub-saturating amounts of Gle1, but was still active as an ATPase and was stimulated by RNA and Gle1 comparable to wild-type protein in the absence of IP~6~ ([Fig. 1d](#F1){ref-type="fig"}). Furthermore, Dbp5^KK→AA^ (L327V variant) no longer formed a stable complex with Gle1^H337R^ and IP~6~ ([Supplementary Fig. 1e](#SD1){ref-type="supplementary-material"}). These results demonstrate that IP~6~ stabilizes the Gle1-Dbp5 interaction by acting as a small-molecule tether.

A comparison of the RNA and ADP BeF~3~-bound Δ90Dbp5 structure with that of Gle1~IP6~-Dbp5 reveals that Gle1~IP6~ in the presence of ADP induces a large rigid body movement in Dbp5, opening the tandem RecA-like domains relative to their positions in the RNA-bound state ([Fig. 1e](#F1){ref-type="fig"} and [Supplementary Movie 1](#SD3){ref-type="supplementary-material"}). Smaller conformational changes occur at the Gle1~IP6~-CTD interface, and structures obtained with wild-type *vs*. gain-of-function mutations show that these mutations subtly alter Gle1~IP6~-Dbp5 contacts, likely contributing additional binding energy to stabilize the complex ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Interestingly, binding to Gle1~IP6~ dramatically alters the RNA binding site in Dbp5, which opens and loses its localized positive charge ([Fig. 1f](#F1){ref-type="fig"} and [Supplementary Movie 2](#SD4){ref-type="supplementary-material"}). This suggests that Gle1~IP6~ binding leads to the formation of a partially open, catalytically-inactive, and ADP-bound complex that precludes RNA binding.

Due to the unexpected similarity between Gle1 and eIF4G, we also compared our structures to the eIF4A/4G complex. The open conformation of Dbp5 induced by Gle1~IP6~ is similar to that described for eIF4A in the presence of eIF4G[@R14], [@R21], [@R22], and there is an overall similarity between the interactions of eIF4G and Gle1~IP6~ with the CTDs of their DEAD-box ATPase partners ([Fig. 2a](#F2){ref-type="fig"}). However, eIF4G lacks an N-terminal helix that in Gle1 forms part of the binding pocket for IP~6~; instead, eIF4G forms a flexible loop that makes additional contacts with eIF4A, effectively compensating for the lack IP~6~ ([Fig. 2b](#F2){ref-type="fig"}). The interface between eIF4G and the eIF4A-NTD also exhibits inter-domain differences when compared to Gle1~IP6~-Dbp5 ([Fig. 2c--d](#F2){ref-type="fig"}), causing eIF4G to stabilize a more open eIF4A intermediate[@R14], [@R21]. Thus, the eIF4G-eIF4A complex appears more competent for ADP exchange than the Gle1~IP6~-Dbp5 complex. Despite these small differences, both Gle1~IP6~ and eIF4G stabilize their DEAD-box binding partner in an open state that is incompatible with RNA binding.

Gle1~IP6~ is a potent activator of the overall ATPase activity of Dbp5[@R10], [@R11], but in our structures, Gle1 is not positioned to directly stimulate ATP hydrolysis ([Fig. 1](#F1){ref-type="fig"}). We therefore hypothesized that Gle1~IP6~ activates Dbp5 by enhancing RNA release, a step known to be rate-limiting in the hydrolytic cycle of other DEAD-box ATPases[@R23], [@R24]. In such a model, product release would rely upon the ability of Gle1~IP6~ to induce the structural rearrangement of the two tandem RecA-like domains of Dbp5 ([Fig. 1e--f](#F1){ref-type="fig"}). Thus, loss of contact between Gle1 and the NTD of Dbp5 should impair the ability of Gle1~IP6~ to activate Dbp5 without affecting the binding between these proteins, which is primarily mediated by the Gle1~IP6~-CTD interaction ([Fig. 1a](#F1){ref-type="fig"}). To test this idea, residues V513, A516, and I520 on a solvent exposed helix of Gle1 ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}), were mutated (Gle1^VAI→DDD^) to disrupt the Gle1-NTD interface ([Fig. 2c](#F2){ref-type="fig"} and [Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}). In an ATPase assay, Gle1^VAI→DDD^ was unable to activate Dbp5 regardless of the presence of RNA and IP~6~ ([Fig. 2e](#F2){ref-type="fig"}), but still formed a complex with Dbp5^L327V^ by gel filtration ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}), demonstrating that these mutations did not disrupt the primary Gle1~IP6~-CTD association.

Next, we directly assessed the effect of Gle1~IP6~ on RNA release from a hydrolysis-deficient Dbp5 mutant, Dbp5^E240Q^, bound to both RNA and ATP ([Fig. 2f](#F2){ref-type="fig"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Dbp5^E240Q^ released RNA very slowly with a t~1/2~ of 180 +/− 15 seconds (k~off~=0.0039 s^−1^) and Gle1~IP6~ stimulated this release \~9-fold (t~1/2~ of 21 +/− 6 seconds, k~off~=0.033 s^−1^). Importantly, no enhancement of RNA release was observed with the Gle1^VAI→DDD^ mutant (166 +/− 50 seconds, k~off~=0.042 s^−1^). Since mutation of Gle1 at these residues *in vivo* resulted in lethality ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}) and Gle1~IP6~ did not affect the ability of Dbp5 to bind or release ADP ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}), we conclude that an essential function of Gle1~IP6~ is to promote RNA release from Dbp5. This may explain how Gle1~IP6~ helps to terminate mRNA export in the cytoplasm.

Given the structural similarities between Gle1~IP6~-Dbp5 and eIF4G-eIF4A, we also tested eIF4G in the same RNA release assay and found that RNA release from eIF4A is similarly stimulated in the presence of its ATPase activator (eIF4A^E172Q^ alone = 55 +/−8 seconds, k~off~ = 0.019+/−0.03 s ^−1^ compared to eIF4A^E172Q^ + eIF4G = 11+/−3 seconds, k~off~ = 0.091 +/− 0.03 s^−1^) ([Fig. 2g](#F2){ref-type="fig"}). This behaviour corresponds well with the \~3X stimulation of ATPase activity reported for eIF4G[@R21]. Together with the structural similarity between Gle1, eIF4G, and other RNA helicase activators such as Upf2, these findings support a model in which Gle1/eIF4G-like proteins generally activate SF1 and SF2 ATPases by promoting RNA release and enzyme recycling.

Recent structural studies of the human Dbp5 ortholog, Ddx19, identified a N-terminal α-helix that lowers basal Dbp5/Ddx19 ATPase activity, but that is also required for RNA-stimulated ATP turnover[@R9], [@R25]. Our structures lack this N-terminal helix, but structural alignments show that Gle1~IP6~ and a C-terminal helix of Dbp5 would clash with this N-terminal domain in the RNA bound state ([Supplementary Fig. 4a--b](#SD1){ref-type="supplementary-material"}). This observation suggests that the autoinhibitory N-terminal helix must be displaced upon Gle1~IP6~ association, and should have little effect on ATPase activity in the presence of Gle1~IP6~. As seen for human Ddx19[@R25], the yeast Δ90Dbp5 construct lacking this regulatory domain displays a basal ATPase rate \~3-fold higher than full- length Dbp5. However, Δ90Dbp5 only reaches the same maximum ATPase level as full-length Dbp5 in the presence of Gle1~IP6~ ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}). This result indicates that release of Dbp5 auto-regulation accounts for a portion of Gle1~IP6~-mediated ATPase stimulation.

Dbp5 is an ATP-dependent RNA binding protein that dissociates from RNA upon each hydrolysis event ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}), and an interaction between full-length Dbp5 and RNA can only be detected at steady-state when turnover is inhibited ([Supplementary Table 3](#SD1){ref-type="supplementary-material"})[@R10]. Intriguingly, deletion of the N-terminal regulatory α-helix within Dbp5 allowed for the formation of a steady-state RNA-Dbp5 complex under conditions of hydrolysis ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}). These data imply that the N-terminal 90 residues of Dbp5 are involved in regulating Dbp5-RNA binding. Furthermore, the observation that Δ90Dbp5 binds RNA ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}), but is not stimulated for hydrolysis by RNA ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}), suggests that these 90 residues play a critical role in the coupling of RNA binding to ATPase activity. To test whether Gle1~IP6~ can alter steady-state RNA binding by displacing this α-helix, we added Gle1~IP6~ to RNA binding assays containing full length Dbp5 and ATP. We observed that addition of Gle1~IP6~ allowed for steady-state binding with an apparent affinity for RNA equal to that measured for Δ90Dbp5 ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). This observation suggests that the N-terminal extension of Dbp5 regulates RNA association, and that Gle1~IP6~ binding can alter this activity. Overall, our results are consistent with a model in which Gle1~IP6~ regulates Dbp5 by: (1) altering the regulatory function of an N-terminal helix within Dbp5, and (2) promoting substrate release through separating the Dbp5 RecA-like domains. Together, these findings explain the robust activation of Dbp5 by Gle1 and the small molecule IP~6~.

In addition to Gle1, Dbp5 interacts with the nucleoporin Nup159 (Nup214 in vertebrates)[@R3], [@R4], [@R8], [@R9],[@R26]. Nup159 and RNA bind to overlapping surfaces on Dbp5, and Nup159 inhibits RNA-dependent ATPase stimulation of Dbp5 *in vitro*[@R9]. To better understand how this potentially inhibitory role of Nup159 contributes to mRNA export, we solved the crystal structure of a Dbp5^L327V^-Gle1^H337R^-Nup159 complex bound to IP~6~ and ADP at a resolution of 2.9 Å (R~work~/R~free~ of 22.9%/26.2%) ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Within this structure, Nup159 interacts with Dbp5 in a manner similar to that of Ddx19 and Nup214[@R9], occluding the RNA binding site, and sterically clashing with the closed, RNA- and ATP-bound state of Dbp5 ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). While the Gle1~IP6~-CTD interface remains relatively static in all of our structures, the Gle1-NTD interface displays distinct structural differences in the presence of Nup159 and now buries only 672 Å^2^ of solvent exposed surface area (compare [Fig. 2c](#F2){ref-type="fig"} and [3b](#F3){ref-type="fig"}). Furthermore, the two RecA-like domains of Dbp5 become further separated in the Dbp5- Gle1~IP6~-Nup159 structure, and the Dbp5 catalytic centre becomes exposed to solvent as functionally critical arginine fingers are pulled out from the nucleotide binding site ([Fig. 3c](#F3){ref-type="fig"}). A comparison of Dbp5 among all structures reveals that inter-domain structural changes proceed along a pair of related arcs, suggesting that Nup159 may further assist Gle1~IP6~ in stabilizing a post-hydrolysis state of Dbp5 to allow for efficient product release at the cytoplasmic face of the NPC ([Supplementary Movie 3](#SD5){ref-type="supplementary-material"}).

To test this biochemically, we assayed Dbp5 ATPase activity and found that upon addition of Gle1~IP6~, Nup159 no longer inhibits ATP turnover ([Fig. 3d](#F3){ref-type="fig"}) indicating that Gle1~IP6~ can overcome the inhibitory effect of Nup159. This suggests that during the hydrolysis cycle in the presence of Gle1, the association of Dbp5 with Nup159 is transient, which is in agreement with the observation that the presence of adenosine nucleotide and/or RNA weakens the Dbp5-Nup159 interaction[@R3], [@R9]. This provides for the possibility that Nup159 not only increases the local concentration of Dbp5 at the NPC[@R4], [@R8], but also cooperates with Gle1 to promote mRNA export. Mechanistically, Gle1 and Nup159 may spatially coordinate the loading of Dbp5 onto an mRNP to target the removal of mRNA-bound export factors and contribute to the overall efficiency of mRNA export[@R4], [@R8], [@R9]. Alternatively, in a non-mutually exclusive model, the Dbp5- Gle1~IP6~-Nup159 structure may represent a post-mRNA export complex formed after mRNP remodelling is complete and Dbp5 is removed from the mRNP. In this model, the interactions of Gle1 and Nup159 with Dbp5 would be critical for enzyme recycling and/or preventing spurious re-binding of Dbp5 to an mRNA in the terminal stages of export.

In conclusion, our study reveals a surprising structural similarity between Gle1 and other helicase regulators including eIF4G and Upf2[@R14], [@R19], [@R21]. Together with our biochemical data, these data suggest a common mode of activation for DEAD-box ATPases and RNA helicases by Gle1/eIF4G-like protein activators. Critical for the activation are a primary stable interaction between the activator and the C-terminal RecA-like domain of the ATPase, and a secondary transient interaction between the activator and the N-terminal RecA-like domain that is required to trigger nucleic-acid release ([Fig. 2](#F2){ref-type="fig"}). For Dbp5, we propose that RNA and Gle1~IP6~/Nup159 promote the formation of closed (ATP binding and hydrolysis) and open (substrate release) conformations of the ATPase, respectively, by influencing the position of the NTD of Dbp5 relative to the CTD ([Fig. 4](#F4){ref-type="fig"} and [Supplementary Movie 3](#SD5){ref-type="supplementary-material"}). Complex disassembly may be further promoted by the \~50-fold ATP-dependent lowering of Dbp5 binding affinity for Nup159 observed in the presence of ATP[@R9], thus allowing Dbp5 to once again bind an mRNA and re-enter the ATPase cycle. For DEAD-box ATPases in general, such a toggling mechanism of the two RecA-like domains could be used to facilitate recycling of enzymes that have just melted RNA duplexes or remodelled RNA-protein complexes. Furthermore, in the presence of additional RNA-binding domains provided in *cis* or *trans*, this activity might also allow for a processive movement of this class of SF2 proteins along an RNA substrate[@R27].

The unique role of IP~6~ as a small molecule tether within the Dbp5-Gle1 complex may allow for IP~6~-dependent fine-tuning of interaction strength. Functionally, this could be used to modulate RNA release/turnover and consequently regulate mRNA export under various growth conditions (e.g. in response to stress). Additional experiments will be needed to elucidate the functional importance of IP~6~ *in vivo*. However, the structural and biochemical framework presented here should guide future experiments not only to determine how Dbp5 in combination with its interaction partners confers directionality to mRNA export, but also to dissect the cellular functions of other RNA helicases and their activators.

Methods Summary {#S1}
===============

Yeast strains and plasmids are listed in [Supplementary Table 4--5](#SD1){ref-type="supplementary-material"}. RNA binding and ATPase assays were performed as described in Methods. ssRNA substrates used for binding and release assays carrying a single fluorescein conjugated UTP were made by *in vitro* transcription. RNA release assays were performed by monitoring the change in fluorescent polarization after rapid 1:1 mixing of DEAD-box protein-RNA binding reactions with excess polyA-RNA using a stopped flow apparatus linked to a Fluoromax-3 fluorimeter. For crystallography, protein purification was performed by affinity and ion exchange chromatography followed by affinity tag cleavage, and complex formation. Protein complexes were separated by gel filtration over a HiPrep Sephacryl S-200 column. Fractions containing the Dbp5-Gle1 or Nup159-Dbp5-Gle1 complex were used for crystal screening in a hanging drop format (200 nL) using a Mosquito robotics platform at 18°C. After 3--7 days of growth, crystals were looped and flash frozen in liquid nitrogen, and diffraction data collected on Beamline 8.3.1 at the Advanced Light Source. Detailed methods and references related to data processing, structure solution, and model building, plus all other methods used are outlined in the Methods section.

Methods {#S2}
=======

Protein purification for crystallography {#S3}
----------------------------------------

Dbp5, Gle1 (a.a. 244--538), Nup159 (a.a. 2--387), eIF4A, and eIF4G (a.a. 572--952) from *S. cerevisiae* were expressed as previously described[@R8], [@R10], [@R21] in BL21-CodonPlus (DE3)-RIPL cells (Strategene) using a combination of nickel affinity, ion exchange, and size exclusion chromatography. For the production of selenomethionine-labeled protein, Dbp5 and Gle1 proteins were purified as above, except that cells were grown in minimal media supplemented with selenomethionine and β-ME and DTT were replaced with TCEP throughout the purification. TEV cleavage was done at a 1:50 ratio (w/w) in 30 mM HEPES (pH 7.5), 400 mM NaCl, 1 mM DTT, 0.25 mM IP~6~, and 10% glycerol at 22°C for 4 hours[@R29]. Following removal of uncleaved protein, by orthogonal purification over a mixture of HIS-Select HF Nickel Affinity Gel (Sigma) and amylose resin (NEB), proteins were mixed in an equimolar ratio, diluted to 150 mM NaCl and concentrated to \~15 mg/mL at 4°C (Amicon Ultra; Millipore). The protein mixture was then further separated by gel filtration over a HiPrep Sephacryl S-200 column (GE Healthcare) at 0.4 ml/min in 10 mM HEPES (pH 7.5), 100 mM NaCl, 1 mM DTT, 0.50 mM IP~6~, and 5% glycerol at 4°C. Fractions containing the desired protein complex, in an equimolar ratio (as judged by SDS-PAGE), were then pooled and concentrated to \~25 mg/mL at 4°C.

Protein crystallization {#S4}
-----------------------

Protein solutions were stored at 4°C and used for crystallization within 1 week, during which time there was no detectable degradation of the proteins. All crystallization was performed in a hanging drop format using a Mosquito robotics platform (TTP LabTech) at 18°C.

The Dbp5-CTD^L327V^/IP~6~/Gle1^H337R^ crystals were grown by mixing 100 nL of selenomethionine-labeled protein solution at 14 mg/mL in gel filtration buffer with 100 nL of a solution containing 30% PEG 3350, 100 mM HEPES pH 8.0, 50 mM NaOAc, and 200 mM LiSO~4~, and incubating for 5 days. Crystals were cryoprotected by dilution into a solution containing 24% PEG 3350, 80 mM HEPES 8.0, 160 mM LiSO~4~, 40 mM NaOAc, 20% glycerol, 0.25 mM IP~6~, 1 mM DTT and 100 mM NaCl, and flash frozen in liquid nitrogen.

The Dbp5-CTD^L327V^/IP~6~/Gle1^WT^ crystals were grown using the same methods as for Dbp5-CTD^L327V^/IP~6~/Gle1^H337R^, but proteins were subjected to gel filtration individually prior to forming 1:1 complexes by direct mixing. Crystallization was performed by mixing 20 mg/mL of selenomethionine-labeled protein solution in gel filtration buffer (with NaCl increased to 150 mM) with a solution containing 30% PEG 3350, 100 mM HEPES 7.8, and 200 mM LiSO~4~ and incubating for 5 days. Crystals were cryoprotected by diluting into a solution containing 24% PEG 3350, 80 mM HEPES 7.8, 160 mM LiSO~4~, 10% glycerol, 0.4 mM IP~6~, 1 mM DTT and 120 mM NaCl, and flash frozen in liquid nitrogen.

The Δ90Dbp5^L327V^/RNA/ADP•BeF~3~ complex was formed by mixing a solution containing unlabeled Δ90Dbp5^L327V^ in gel filtration buffer (with the addition of 5 mM MgCl~2~) with a 1.2:1 molar ratio of rU~10~ RNA (IDT), incubating for 15 minutes, and then mixing with ADP•BeF~3~ (prepared in a 1:3:15 ratio of ADP:Be:F) to a final concentration of 1 mM, followed by another 15 minutes of incubation. Crystals of the Δ90Dbp5^L327V^/RNA/ADP•BeF~3~ complex were grown by mixing 100 nL of the complex at a protein concentration of 15 mg/mL with 100 nL of a solution containing 200 mM MgNO~3~ and 20% PEG 3350 (Qiagen "The PEGs Suite" condition \#64) and incubating for 7 days. Crystals were cryoprotected by diluting in a solution containing 18% PEG 3350, 9 mM HEPES pH 7.5, 180 mM MgNO~3~, 4.5% glycerol, 1 mM DTT, 90 mM NaCl, 0.5 mM IP~6~, 4.5 mM MgCl~2~ and 1 mM ADP BeF~x~ (prepared in a 1:3:15 ratio of ADP:Be:F), and flash frozen in liquid nitrogen.

The Δ90Dbp5^L327V^/IP~6~/Gle1^H337R^ /ADP complex was formed by mixing the unlabeled protein solution with ADP to a final concentration of 0.5 mM incubated for 15 minutes. Crystals were grown by mixing 200 nL of a solution containing 30% PEG 300 and 100 mM MES pH 6.5 with 50 nL of a 10% MPD additive solution, adding 250 nL of protein/ADP complex at 15 mg/mL protein in gel filtration buffer (with the addition of 10 mM MgCl~2~), and incubating for 9 days. Crystals were cryo-protected by diluting in a solution containing 27% PEG 3350, 90 mM MES pH 6.5, 9 mM HEPES pH 7.5, 5.4% MPD, 90 mM NaCl, 9 mM MgCl~2~, 0.9 mM DTT, 0.9 mM ADP, 0.45 mM IP~6~ and 4.5% glycerol and flash frozen in liquid nitrogen. The Δ90Dbp5/RNA/ADP•BeF3 crystals were grown in the same manner using wild type Δ90Dbp5.

The Nup159/Δ90 Dbp5^L327V^/IP~6~/Gle1^H337R^/ADP complex was formed by mixing the unlabeled protein solution with ADP to a final concentration of 1.0 mM, and incubating for 15 minutes. Crystals were grown by mixing 200 nL of a solution containing 20% PEG 3350 and 200 mM KOAc with 50 nL of a 100 mM sarcosine additive solution, adding 250 nL of protein/ADP complex at 15 mg/mL protein in gel filtration buffer (with the addition of 10 mM MgCl~2~), and incubating for 5 days. Crystals were cryo-protected by diluting in a solution containing 27% PEG 3350, 180 mM KOAc, 90 mM NaCl, 9 mM HEPES pH 7.5, 9 mM sarcosine, 9 mM MgCl~2~, 0.9 mM DTT, 0.9 mM ADP, 0.45 mM IP~6~ and 4.5% glycerol and flash frozen in liquid nitrogen.

Data collection, structure solution and refinement {#S5}
--------------------------------------------------

All data were collected at beamline 8.3.1 at the Advanced Light Source at 100 Kelvin[@R30], and processed using either HKL2000 or ELVES[@R31], [@R32](see also below). Structures were solved with the AutoSol or AutoMR components of PHENIX[@R33]. Iterative rounds of manual model building in COOT[@R34], coupled with refinement using PHENIX[@R33] and stereochemical validation using MOLPROBITY[@R35], resulted in final models displaying excellent geometry and R~work~/R~free~ values for their respective resolutions, as well as no Ramachandran outliers. Rigid body refinement was conducted on Gle1 and Dbp5 RecA-like domains for all structures solved by molecular replacement in order to reveal any rigid-body differences among the structures. Simulated annealing omit maps were calculated to confirm the presence of all ligands ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). For all structures solved by molecular replacement, simulated annealing composite omit maps and prime and switch maps, both made using the AutoBuild component of PHENIX[@R33], were calculated to help remove model bias.

Multiwavelength anomalous dispersion (MAD) data were collected at wavelengths of 0.9796, 0.9798, and 1.020 Å for the Dbp5-CTD^L327V^/IP~6~/Gle1^H337R^ crystals in inverse beam mode and processed in HKL2000[@R31] ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The structure was solved using PHENIX AutoSol, which found 11 selenium sites and gave figures of merit of 0.5 and 0.7 for phasing and density modification, respectively. An initial model was built using PHENIX AutoBuild[@R33]. For the final model, atomic coordinates, individual atomic displacement parameters (B-factors), translation/libration/screw (TLS) parameters, and f' and f'' parameters for the Se atoms were refined against the unmerged Friedel pairs (F+ and F−) of the remote dataset as implemented in PHENIX. Ramachandran statistics are 98.3% preferred, 1.7% allowed and 0% outliers as reported by Molprobity[@R35].

A single low energy remote dataset was collected at a wavelength of 1.116 Å for the Dbp5-CTD^L327V^/IP~6~/Gle1^WT^ crystals and processed in HKL2000 with merging of Friedel pairs. The structure was solved using PHENIX AutoMR by searching for a single copy of the fully refined Dbp5-CTD^L327V^/IP~6~/Gle1^H337R^ structure[@R33]. For the final model, atomic coordinates, individual atomic displacement parameters (B-factors), and translation liberation screw (TLS) parameters were refined. The refinement test set was copied from the isomorphous Dbp5-CTD^L327V^/IP~6~/Gle1^H337R^ data and extended to higher resolution in order to avoid biasing the R~free~. Ramachandran statistics are 98.0% preferred, 2.0% allowed and 0% outliers as reported by Molprobity[@R35].

Native data were collected on the Δ90Dbp5^L327V^/RNA/ADP•BeF~3~ crystals at a wavelength of 1.116 Å and processed in HKL2000. The structure was solved using PHENIX AutoMR by searching for a single copy of a *Saccharomyces cerevisiae* Dbp5 homology model (SWISS-MODEL) [@R33], [@R36], created using the human Ddx19/RNA/AMPPNP structure as a template (PDB: 3G0H)[@R25]. For the final model, atomic coordinates, individual atomic displacement parameters (B-factors), TLS parameters, and occupancies for residues with alternate conformations were refined. Custom bond restraints were used for octahedral Mg^2+^-H~2~O clusters and the ADP BeF~3~ molecule. Ramachandran statistics are 99.2% preferred, 0.8% allowed and 0% outliers as reported by Molprobity[@R35].

Native data were collected on the Δ90Dbp5^WT^/RNA/ADP•BeF~3~ crystals at a wavelength of 1.116 Å and processed in HKL2000. The structure was solved using PHENIX AutoMR by searching for a single copy of the fully refined Δ90Dbp5^L327V^/RNA/ADP•BeF~3~ structure and refined in the same manner[@R33]. Ramachandran statistics are 98.5% preferred, 1.5% allowed and 0% outliers as reported by Molprobity[@R35].

Native data were collected on the Δ90 Dbp5^L327V^/IP~6~/Gle1^H337R^/ADP crystals at a wavelength of 1.116 Å and processed in Elves. The structure was solved using PHENIX AutoMR by searching for a single copy of the fully refined Gle1^H337R^/IP~6~/Dbp5-C^L327V^ structure and a single copy of the Dbp5-NTD (residues 101--293) of the fully refinedΔ90Dbp5^L327V^/RNA/ADP•BeF~3~ structure[@R33]. B-factor sharpening was used throughout model building. Initial F~o~--F~c~ difference density showed that two additional IP~6~ molecules were present in the structure. While the IP~6~ molecules have high relative B-factors, they mediate crystal-packing contacts and are coordinated by a large number of basic and polar residues. For the final structure, atomic coordinates and TLS parameters were refined. Secondary structure restraints as implemented in PHENIX were used throughout refinement in order to maintain proper backbone geometry. Ramachandran statistics are 97.6% preferred, 2.4% allowed and 0% outliers as reported by Molprobity[@R35].

Native data were collected on the Nup159/Δ90 Dbp5^L327V^/IP~6~/Gle1^H337R^/ADP crystals at a wavelength of 1.116 Å and processed in HKL2000. The structure was solved using PHENIX AutoMR by searching for a single copy each of Gle1, the Dbp5-NTD, the Dbp5-CTD and Nup159 (PDB: 1XIP)[@R8], [@R33]. For the final model, atomic coordinates, and TLS parameters were refined. Ramachandran statistics are 97.3% preferred, 2.7% allowed and 0% outliers as reported by Molprobity[@R35].

Structural analysis {#S6}
-------------------

All structural analysis and rendering for figures was performed with PyMOL (Schrödinger, LLC). Solvent accessible electrostatics in [Figure 1](#F1){ref-type="fig"} was calculated using ABPS[@R37]. Energy minimized linear interpolations shown in [Supplementary Movies 1--3](#SD3){ref-type="supplementary-material"} were made using a CNS script written by the Yale Morph Server[@R38], [@R39]

Complex formation and gel filtration {#S7}
------------------------------------

To assay for Dbp5-Gle1 complex formation, 100 μL of a binding reaction was applied to a Superdex 200 gel filtration column (GE Healthcare) in the presence of 30 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM DTT, 0.25 mM IP~6~, and 5% glycerol at 0.4 mL/min. Binding reactions contained Dbp5 (20 μM) and Gle1 (40 μM) mixed with column buffer.

ATPase assays {#S8}
-------------

ATPase assays using Dbp5 were performed as previously described[@R10]. When present, Nup159 was added to a final concentration of 1 μM.

RNA binding and release assay {#S9}
-----------------------------

The RNA substrate used for the binding and release assays was a 29 nt ssRNA of the sequence 5′-GGGUAAAAAAAAAAAAAAAAAAAAAAAAA-3′for Dbp5 or a 25 nt ssRNA of the sequence 5′-GGGUACAACGGAAGACAGCAGAGAA for eIF4A carrying a fluorescein conjugated UTP made by *in vitro* transcription (MEGAshortscript Kit; Ambion). RNA binding assays were performed as previously described[@R10], [@R40]. To perform RNA release assays, Dbp5^E240Q^ (1.0 μM) or eIF4A^E172Q^ (4.0 μM), FITC-RNA (40 nM), and ATP (2 mM) +/− Gle1 (2.0 μM) or eIF4G (8.0 μM) were complexed for 5 minutes in a buffer containing 50 mM HEPES (pH 7.5), 140 mM KCl, 5 mM MgCl~2~, 1 mM DTT, 20% glycerol, 0.1mg/mL BSA, and 10 μM IP~6~ for Dbp5 or 20 mM MES (pH 6.0), 20 mM KOAc, 5 mM MgCl~2~, 1 mM DTT, 20% glycerol, and 0.1mg/mL BSA for eIF4A. After rapid 1:1 mixing of DEAD-box-RNA binding reactions with polyA-RNA (1.0 mg/mL) using a stopped flow apparatus (RX2000; Applied Photophysics) linked to a Fluoromax-3 fluorimeter (Horiba Jobin Yvon), fluorescence intensities were measured every 0.05 to 0.2 seconds depending on the reaction. To measure fluorescent polarization, samples were excited with vertically polarized light (492 nM), and emission (521 nM) of vertically (I~VV~) and horizontally (I~VH~) polarized light was measured independently in two consecutive runs. Anisotropy (r) was then calculated using the equation: r = (I~VV~ − (G × I~VH~))/(I~VV~ + (2 × G × I~VH~)), where G = I~HV~/I~HH~. Reported t~1/2~ values are an average of three independent experiments +/− standard deviation. Release curves were fit to a first order exponential decay curve using KaleidaGraph (Synergy Software).

MANT-ADP binding and release assays {#S10}
-----------------------------------

MANT-ADP labeled at the 2′- or 3′ position of the base (Invitrogen) was used for the binding and release assays with Dbp5^E240Q^. MANT-ADP binding assays were performed in a manner similar to the RNA binding assay[@R10]. Briefly, Dbp5^E240Q^ (0--2 μM) and MANT-ADP (100 nM) were mixed with buffer (50 mM HEPES (pH 7.5), 140 mM KCl, 5 mM MgCl~2~, 1 mM DTT, 20% glycerol, 0.1mg/mL BSA, and 10 μM IP~6~) and RNA (1mg/mL) or Gle1 (2 μM) as indicated. Following mixing, anisotropy was measured using a Fluoromax-3 fluorimeter (Horiba Jobin Yvon). To perform the release assay, Dbp5^E240Q^ (1 μM) was complexed with MANT-ADP (100nM) for 5 minutes +/− Gle1 (2 μM) and/or RNA (1mg/mL) in a buffer containing 50 mM HEPES (7.5), 140 mM KCl, 5 mM MgCl~2~, 1 mM DTT, 20% glycerol, 0.1mg/mL BSA, and 10 μM IP~6~. After rapid 1:1 mixing of Dbp5-MANT-ADP reactions with excess ADP (2 mM) using a stopped flow apparatus (RX2000; Applied Photophysics) linked to a Fluoromax-3 fluorimeter (Horiba Jobin Yvon), fluorescence intensities were measured every 0.01 seconds using 370 nM (excitation) and 445 nM (emission) light. Fluorescent polarization and t~1/2~ values were calculated as described above in the RNA release assays.
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![The Gle1~IP6~-Δ90Dbp5-ADP complex\
**a,** Structure of Dbp5 bound to ADP (magenta spheres) and Gle1 (see colour key). **b,** Side view showing IP~6~ (coloured spheres) bound at the interface between Gle1 and Dbp5. **c,** Detailed view of the IP~6~ binding interface (see colour key). IP~6~ is shown as grey sticks with orange phosphate and red oxygen atoms. Nitrogen atoms are in dark blue. **d,** IP~6~ binding is required for maximal Dbp5 ATPase stimulation with RNA. Error bars represent s.d. (n=3). **e,** Structural superposition of the RNA-Δ90Dbp5 complex with Gle1~IP6~-Δ90Dbp5. Arrows depict large rigid body movement in Dbp5. **f,** Van der Waals surface view of the RNA-Δ90Dbp5 complex and the Gle1~IP6~-Δ90Dbp5 complex coloured by solvent accessible electrostatics. Abbreviations: k~b~ -- Boltzmann's constant (Joules/Kelvin), T -- temperature (310 Kelvin), e~c~ -- charge of an electron (1.602 x 10^−19^ Coulombs).](nihms266350f1){#F1}

![Comparison of Gle1~IP6~-Δ90Dbp5 and eIF4A-eIF4G\
**a,** Structural superposition of Gle1~IP6~-Δ90Dbp5 with eIF4G-eIF4A and AMP (PDB ID: 2VSO)[@R21] (see colour key). **b,** View of the C-terminal RecA-like domain binding interface. Unique α-helices present in both Dbp5 and Gle1 form the IP~6~ biding pocket (boxed in figure). **c, d,** Residues involved in the formation of the N-terminal RecA-like domain binding interface in (**c**) Gle1~IP6~-Δ90Dbp5 and (**d**) eIF4A-eIF4G. **e,** Measured ATPase activity using wild type or mutant Gle1. Error bars represent s.d. (n=3). **f, g,** RNA release from Dbp5^E240Q^ or eIF4A^E172Q^ monitored by fluorescence polarization. Representative curves are shown.](nihms266350f2){#F2}

![The Gle1~IP6~-Δ90Dbp5-Nup159 complex\
**a**, Two views of the Gle1~IP6~-Dbp5-Nup159 complex (see colour key). **b,** The N-terminal RecA-like domain binding interface between Dbp5- Gle1~IP6~ is altered in the presence of Nup159 (compare to [Fig. 2c](#F2){ref-type="fig"}). Residues involved in the binding interface (sticks) are labelled. **c,** Superposition of the N-terminal RecA-domain among the three structural states of Dbp5. Arrow highlights the movement of the CTD and catalytic arginine finger residues (sticks) among the three states (see colour key). For clarity, the Gle1-ADP intermediate is shown slightly transparent, and both the arginine finger side chains and ADP have been removed. **d,** Inhibition of the RNA stimulated ATPase activity of Dbp5 by Nup159 is overcome in the presence of Gle1. Error bars represent s.d. (n=3).](nihms266350f3){#F3}

![Model of the Dbp5 mechanochemical cycle\
In the presence ATP, Dbp5 binds RNA causing local destabilization and remodelling of duplexed RNA or RNA-protein complexes (state I). ATP hydrolysis then allows the activator (Gle1) to bind both the C-terminal and N-terminal RecA-like domains, separating the two RecA-like domains and promoting RNA release (state II). For Dbp5 it is currently not known when P~i~ is released following hydrolysis, but this will likely occur prior to the formation of state II. Subsequent release of the bound RNA allows Nup159 to bind Dbp5 causing the two RecA domains to further separate (state III). The formation of this state could then facilitate ADP release, prevent rebinding of the RNA, and aid in enzyme recycling (state IV). Crystal structure model in state IV is PDB ID:3FHO[@R28]. For colour coding details see key.](nihms266350f4){#F4}
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